JPRN-UMIN000011878已完成1 期
A phase 1 clinical pharmacological study with a single oral dose of KAG-308 - A phase 1 clinical pharmacological study of KAG-308
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 45years-old（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •1. The subject with failure or medical history of central nervous system disease, cardiac disease, or failure of cardiovascular, respiratory, blood and hematopoietic function system, gastrointestinal system, liver and renal function, thyroid function, pituitary function, adrenal function, etc. And the subject concluded by principal investigator (or sub investigators) difficult to ensure safety during the study. 2. The subject who does not meet the criteria of "clinical laboratory test, vital sign, 12 lead electrocardiograms". 3. The subject who tested positive after either HIV test, HBV test, HCV test, syphilis test, or tuberculosis test. 4. The subject with medical history of gastrointestinal tract symptom or gastrointestinal tract resection that affects pharmacokinetics. 5. The subject who is using drug or receiving therapy. 6. The subject with drug allergy or medical history. 7. The subject who felt sick at the time of blood donation or blood collection. 8. The subject who had been taken blood (blood donation, etc.) of more than 400 mL 90 days before the starting day of administration of the study drug, or the subject with the annual volume of blood collection more than 1200 mL including this study. 9. The subject who cannot stop either drinking alcohol during hospitalization or smoking from the day before the date of admission until the day of discharge. 10. The subject who tested positive on a urine abusable drug test. 11. The subject who is administered other study drug within 112 days past (16 weeks) before the scheduled administration date of the study drug. 12. The stuff of the institution or employees of the sponsor.
研究者
相似试验
招募中
不适用
A phase I study to evaluate the pharmacokinetic interactions and safety between Amlodipine/Valsartan combination tablet and Rosuvastatin in healthy adult volunteersDiseases of the circulatory systemKCT0001660Kyung Dong Pharmaceutical57
已完成
1 期
A study in healthy volunteers to investigate how the test medicine CORT113176 is taken up by the body when given with food and without foodAmyotrophic lateral sclerosis (ALS)Nervous System DiseasesMotor neuron diseaseISRCTN52169163Corcept Therapeutics (United States)35
进行中（未招募）
1 期
A Phase I study to investigate the pharmacokinetics and ECG effects of two single ascending doses of linaprazan glurate given as oral tablets to healthy subjectsErosive Gastroesophageal Reflux Disease (eGERD)MedDRA version: 20.1Level: LLTClassification code: 10017924Term: Gastroesophageal reflux Class: 10017947CTIS2024-516261-36-00Cinclus Pharma Holding AB (publ)63
已完成
1 期
A phase I study to assess the pharmacokinetics of a single dose of a slow-release solid injection of EPT1647 in healthy male volunteers/AHealthy male volunteersOther -ACTRN12605000782639Epitan Limited6
招募中
1 期
A pilot study of the pharmacokinetics, efficacy, and acceptability of a novel nicotine inhaler in smokersTobacco use disorderNicotine addictionMental Health - AddictionACTRN12606000423516Professor Julian Crane10